Big pharma strikes blow to NHS patients’ hopes of getting breakthrough drugs

Big pharma strikes blow to NHS patients’ hopes of getting breakthrough drugs NHS patients risk missing out on breakthrough drug treatments after two leading pharmaceutical companies pulled out of the UK’s official pricing scheme.

Eli Lilly and AbbVie have left the voluntary scheme for branded medicines pricing and access (VPAS), a long-standing agreement between the Government, NHS and medicine manufacturers designed to limit the cost of drugs for the health service while supporting industry innovation. The Daily Telegraph

See also:

• AbbVie and Eli Lilly and Company, two of the world’s largest pharmaceutical companies, have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks. Association of the British Pharmaceutical Industry
• AbbVie and Eli Lilly snub drug pricing agreement PharmaTimes